

By: Springer, Hall

S.B. No. 403

A BILL TO BE ENTITLED

1 AN ACT  
2 relating to a study on the adverse reactions and efficacy of  
3 COVID-19 vaccines.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

5 SECTION 1. DEFINITIONS. In this Act:

6 (1) "Center" means The University of Texas Health  
7 Science Center at Houston.

8 (2) "COVID-19" means the disease associated with  
9 exposure from:

10 (A) the SARS-CoV-2 virus, including any variants  
11 of the virus; or

12 (B) a COVID-19 vaccine injection.

13 (3) "Department" means the Department of State Health  
14 Services.

15 (4) "Vaccine" means a substance used to stimulate  
16 immunity to a particular infectious disease or pathogen.

17 SECTION 2. STUDY. (a) The department, in collaboration  
18 with the center, shall conduct a study to assess the full scope of  
19 adverse reactions, including death, and efficacy of COVID-19  
20 vaccines used in this state.

21 (b) In conducting the study, the department shall compile  
22 information regarding:

23 (1) the immediate short-term side effects and adverse  
24 reactions experienced by vaccine recipients, including:

1 (A) pain, swelling, or redness at the vaccine  
2 injection site;

3 (B) mild fever;

4 (C) chills;

5 (D) tiredness;

6 (E) headache; and

7 (F) muscle or joint aches;

8 (2) the immediate serious side effects and adverse  
9 reactions experienced by vaccine recipients, including:

10 (A) difficulty breathing;

11 (B) swelling of the face or throat;

12 (C) accelerated heartbeat;

13 (D) body rash;

14 (E) dizziness; and

15 (F) weakness;

16 (3) the long-term side effects and adverse reactions  
17 experienced by vaccine recipients, including:

18 (A) paralysis;

19 (B) myocarditis;

20 (C) clotting disorders;

21 (D) thrombosis with thrombocytopenia syndrome;

22 (E) Guillain-Barré syndrome;

23 (F) difficulty thinking or brain fog;

24 (G) chronic pain;

25 (H) tiredness or fatigue;

26 (I) loss of taste;

27 (J) depression;

1 (K) anxiety; and

2 (L) death; and

3 (4) any misrepresentation or concealment regarding  
4 the efficacy or dangers of vaccination by the vaccine manufacturer  
5 or a governmental agency.

6 (c) In conducting the study, the department and the center  
7 shall compile and make available information described by  
8 Subsection (b) of this section, including information collected by:

9 (1) the department, including information collected  
10 by the department's vital statistics unit, and center;

11 (2) hospitals or treatment centers;

12 (3) any available survey;

13 (4) public hearings that involve health care  
14 providers, researchers, injured patients, or the families of  
15 injured patients speaking on COVID-19 or COVID-19 vaccine  
16 experiences, including difficulties prescribing or filling  
17 therapeutic prescriptions and difficulties encountered in  
18 hospitals or with any medical boards; and

19 (5) any other relevant source, including the Vaccine  
20 Adverse Event Reporting System maintained by the Centers for  
21 Disease Control and Prevention and the Defense Medical Epidemiology  
22 Database maintained for the United States Department of Defense.

23 SECTION 3. REPORT. Not later than January 1, 2024, the  
24 department shall prepare and submit to the governor, lieutenant  
25 governor, speaker of the house of representatives, and chairpersons  
26 of legislative standing committees with jurisdiction over health  
27 and safety a written report summarizing the information compiled in

1 the study and any recommendations for legislative or other action  
2 to reduce the prevalence of COVID-19 vaccine side effects. The  
3 department may make the report available to the public and post the  
4 report on the department's Internet website.

5 SECTION 4. EXPIRATION. This Act expires September 1, 2025.

6 SECTION 5. EFFECTIVE DATE. This Act takes effect  
7 immediately if it receives a vote of two-thirds of all the members  
8 elected to each house, as provided by Section 39, Article III, Texas  
9 Constitution. If this Act does not receive the vote necessary for  
10 immediate effect, this Act takes effect September 1, 2023.